Breast cancer is largely categorized into the luminal, HER2+, and triple-negative breast cancer subtypes based on their immunohistochemical expression pattern of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2) [8,9]. This evidence concerns the gene ERBB2 and breast carcinoma.